CH
BMRN icon

Cromwell Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cromwell Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69K Buy
47
+13
+38% +$712 ﹤0.01% 789
2026
Q1 		$1.92K Hold
34
– – ﹤0.01% 724
2025
Q4 		$2.02K Hold
34
– – ﹤0.01% 692
2025
Q3 		$1.84K Buy
34
+13
+62% +$743 ﹤0.01% 714
2025
Q2 		$1.15K Buy
21
+7
+50% +$412 ﹤0.01% 778
2025
Q1 		$990 Buy
+14
New +$942 ﹤0.01% 658

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Cromwell Holdings's BMRN Position: Q2 2026 in Review

Cromwell Holdings increased its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, buying an estimated $712 and bringing the position to 47 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Cromwell Holdings first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Cromwell Holdings held 47 shares of BioMarin Pharmaceuticals worth $2.69K as of Q2 2026.
  • Cromwell Holdings bought 13 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $712.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Cromwell Holdings's portfolio in Q2 2026, its #789 holding.
  • Cromwell Holdings first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.